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Tostanoski et al. show that a single direct
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mouse model of multiple sclerosis
underpinned by myelin attack. This local
reprogramming of the lymph node
microenvironment toward regulatory
function drives tolerance that is systemic
but myelin specific.
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Many experimental therapies for autoimmune dis-
eases, such as multiple sclerosis (MS), aim to bias
T cells toward tolerogenic phenotypes without broad
suppression. However, the link between local signal
integration in lymph nodes (LNs) and the specificity
of systemic tolerance is not well understood. We
used intra-LN injection of polymer particles to study
tolerance as a function of signals in the LN micro-
environment. In a mouse MS model, intra-LN intro-
duction of encapsulated myelin self-antigen and a
regulatory signal (rapamycin) permanently reversed
paralysis after one treatment during peak disease.
Therapeutic effects were myelin specific, required
antigen encapsulation, and were less potent without
rapamycin. This efficacy was accompanied by local
LN reorganization, reduced inflammation, systemic
expansion of regulatory T cells, and reduced T cell
infiltration to the CNS. Our findings suggest that local
control over signaling in distinct LNs can promote
cell types and functions that drive tolerance that is
systemic but antigen specific.
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disease that occurs
when self-reactive CD4+ T cells enter the CNS, recognize myelin
self-antigen, secrete inflammatory cytokines, and recruit addi-
tional infiltrating myelin-specific T cells and antibodies (Coma-
bella andKhoury, 2012; Dendrou et al., 2015). These effects drive
demyelination of neurons, destruction of oligodendrocytes, and
loss of motor function that traditionally have been treated using
non-specific, systemic immunosuppression (Piehl, 2014). The
need for more effective and selective therapeutic options has2940 Cell Reports 16, 2940–2952, September 13, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://sparked intense interest in vaccine-like strategies that promote
myelin-specific tolerance (Lutterotti and Martin, 2014; Steinman
et al., 2012). For example, several recent reports have studied
the administration of myelin, cytokines, or immunomodulatory
drugs to bias T cell differentiation away from inflammatory sub-
sets (e.g., TH1 and TH17) and toward regulatory T cells (TREGS)
without broad suppression (Esposito et al., 2010; Ho et al.,
2005; Lutterotti and Martin, 2014; Northrup et al., 2016).
Recently, nanoparticles (NPs) have been explored as carriers of
self-antigens or tolerogenic signals (Gammon et al., 2015; Getts
et al., 2012; Hunter et al., 2014; Kontos et al., 2013; Look et al.,
2013; Maldonado et al., 2015; Northrup et al., 2014; Tsai et al.,
2010; Yeste et al., 2012) because biomaterials can enhance deliv-
ery and targeting of cell types (e.g., dendritic cells [DCs]) that play
an important role in controlling tolerance (Andorko et al., 2015;
Manicassamy and Pulendran, 2011; Northrup et al., 2016). Find-
ings from several studies indicate NP-mediated co-delivery of
self-antigen and regulatory cues drives a synergistic effect in re-
straining mouse models of MS (Maldonado et al., 2015; Yeste
et al., 2012). However, other reports, such as those of Miller,
Shea, and colleagues, demonstrate that NPs loaded with or dis-
playing self-antigen alone can promote tolerance (Clemente-Ca-
sares et al., 2016; Getts et al., 2012; Hunter et al., 2014). Thus,
the unique role of each component in controlling self-reactivity
is unclear. Whereas these past approaches used systemic or pe-
ripheral injection routes, here we used direct lymph node (LN) de-
livery as a tool to isolate the impact of self-antigen and regulatory
cues on the local function of injected LNs, the resultant effects on
non-treated tissues, and, ultimately, the progression of disease.
This approachwasmotivated by the fact that T cell polarization
occurs in the spleenandLNs, tissues that coordinate adaptive im-
munity (Mueller and Germain, 2009) but that are anatomically
distinct from the site of attack in MS and other tissue-specific
autoimmune diseases. Thus, LNs play a critical role in defining
the inflammatory or regulatory functions of T cells that eventually
migrate to sites of disease. This relationship is further evidenced
by the clinical success of natalizumab, a monoclonal antibodyuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Intra-nodal Injection of MPs to
Promote Tolerance
(A) Direct control over LN signaling via i.LN. injec-
tion of MPs encapsulating immune cues is shown.
(B) Immunofluorescent image shows inguinal LN
excised 30 min after i.LN. injection with fluores-
cent MPs (red) encapsulating fluorescent MOG
peptide (green) and Rapa. B cells, B220 (blue);
T cells, CD3e (white). Scale bar, 100 mm.
(C) Mean clinical score of mice induced with EAE
and treated i.LN. on day 10 (Tx, red arrow) with
empty MPs (n = 8), MOG MPs (n = 12), Rapa MPs
(n = 8), or MOG/Rapa MPs (n = 12). Statistics are
shown in (D) and (E) for clarity.
(D) Mean clinical scores at day 19 are shown.
(E) Mean clinical scores of mice in (C) that devel-
oped symptoms (Part. Resp.) after MOG MP or
MOG/Rapa MP treatment.
Statistical analysis in (D) was performed using
one-way ANOVA with a Tukey post-test and in
(E) using multiple t tests, one at each time
point, with a Holm-Sidak post-test correction for
multiple comparisons. Data in all panels represent
mean ± SEM (*p% 0.05, **p% 0.01, ***p% 0.001,
and ****p % 0.0001). See also Table S1 and
Figures S1 and S2.that non-specifically blocks lymphocyte migration across the
blood-brain barrier (Cross and Naismith, 2014), underscoring
the link between pathogenic cells armed in the periphery and infil-
tration into the CNS to drive disease. In addition, a network of
lymphatic vessels recently was discovered in the brains of mice
and shown to communicate directly with peripheral LNs (Aspe-
lund et al., 2015; Louveau et al., 2015). This landmark finding sug-
gests new routes by whichmyelin self-antigenmight exit the CNS
for processing in draining LNs, where the local microenvironment
controls the response to incoming antigens. However, direct
study of the link between local LN signaling and systemic toler-
ance previously has been hindered by poor control over how
therapeutic cues are trafficked to and processed in LNs following
injection via conventional routes.
We recently reported that direct, intra-LN (i.LN.) delivery of
degradable polymer depots can be used to retain encapsulated
adjuvants in LNs and drive potent expansion of antigen-specific
effector T cells against model antigens (Andorko et al., 2014;
Jewell et al., 2011). We hypothesized this platform could be ex-
ploited to study how spatially localized self-antigen and tolero-
genic immune cues in LNs impact the progression of autoim-
mune disease. Since many vaccines and immunotherapies
must ultimately reach LNs or spleen for efficacy, this knowledge
could inform new therapies, irrespective of injection route, while
also indicating the clinical potential of controlling local LN func-
tionwith polymer depots. Using two immune cueswidely studied
in recent tolerogenic vaccines, a peptide fragment of myelin
oligodendrocyte glycoprotein (MOG) and rapamycin (Rapa),
we show that a single i.LN. dose of particles administered at
the peak of disease reverses disease-induced paralysis. In
our research, efficacy is dependent on localization of depotsto LNs, requires encapsulation of myelin self-antigen, and is
enhanced when Rapa is co-incorporated in depots along with
MOG. Underlying the functional effects is a local reorganization
in cell composition of the injected LNs that results in systemic re-
straint of inflammation and polarization of CD4+ T cells toward
TREGS. These changes also are accompanied by the formation
of tolerogenic structural subdomains in both treated LNs and
non-treated CNS-draining LNs, as well as a decrease in the fre-
quency of T cells infiltrating CNS tissue.
RESULTS
i.LN. Injection of Depots Co-loaded with MOG and Rapa
Confers Synergistic Restraint of Autoimmunity
Our previous studies using inflammatory signals for pro-immune
vaccination revealed that particles with diameters of several mi-
crons or moremaximized retention in LNs following i.LN. injection
(Jewell et al., 2011). Thus, a double-emulsion process was used
to prepare degradable poly(lactide-co-glycolide) microparticle
(MP) depots in this size range, encapsulating various combina-
tions of MOG and Rapa. MP formulations were then introduced
into the inguinal LNs of mice (Andorko et al., 2014; Jewell et al.,
2011), utilizing a common model of MS, experimental autoim-
mune encephalomyelitis (EAE). We used this approach to study
the local impact of each component on treated nodes, corre-
sponding changes in non-injected LNs, spleen, and CNS, as
well as how these effects alter the nature and specificity of sys-
temic tolerance during CNS autoimmunity (Figure 1A).
Immunofluorescent analysis was first used to confirm i.LN. in-
jection localized MPs in LNs. Fluorescently labeled MPs and
cargo were detected dispersed throughout the LN paracortex,Cell Reports 16, 2940–2952, September 13, 2016 2941
without disrupting the classic arrangement of B and T cell zones
(Figure 1B). Myelin self-antigen and Rapa are two of the most
intensely studied molecules in tolerance therapies, having
been explored independently in models of MS and also recently
shown to exert synergistic effects when administered systemi-
cally (Maldonado et al., 2015). Thus, we next designed experi-
ments to decipher the roles of MOG and Rapa in the develop-
ment and maintenance of tolerance following i.LN. injection.
Mice were induced with EAE and 10 days later, to mimic an early
therapeutic intervention, immunized i.LN. with MPs encapsu-
lating MOG, Rapa, or both (Table S1). A control group of empty
MPs (i.e., polymer and stabilizer only) exhibited no significant
effect on the severity of clinical scores compared with induced,
untreated mice (Figure S1). Similarly, MPs encapsulating Rapa
alone had no impact on EAE measured by clinical score (Figures
1C and 1D), incidence of disease (Figure S2), and weight loss—
an indirect indicator of disease (Figure S2).
In contrast, bothMOGMPs andMOG/RapaMPsmarkedly and
permanently reduced the onset and severity of clinical EAE scores
(Figures 1C and S2) and weight loss (Figure S2), with co-loaded
MPs conferring a synergistic therapeutic effect in attenuating
disease severity. In particular, at time points corresponding to
the development of EAE symptoms in MOG MP-treated mice,
MOG/Rapa MP-treated mice remained almost completely
asymptomatic (Figures 1D and S2). Although MOG/Rapa MPs
generally delayed disease onset relative to MOG MPs, there
was only a modest difference in the final incidence of disease be-
tween the two groups, 33.3% versus 50%, respectively (Fig-
ure S2). The MOG/Rapa MP treatment exhibited a trend of less
severe disease, with a 2.70-point reduction in final mean score
relative to empty MP-treated mice, compared with a 1.90-point
reduction in MOG MP-treated mice. However, most pronounced
was the result that, amongmice that did develop disease, termed
partial responders, MOG/Rapa MPs (final clinical score of 0.90 ±
0.29) significantly decreased the severity of paralysis compared
with MOG MPs (final clinical score of 2.33 ± 0.51; Figure 1E).
To assess the functional impact of i.LN. treatments on patho-
genic cell infiltration into the CNS, spinal cords were collected
5 days after MP treatment (i.e., day 15 post-EAE induction),
and sections were analyzed for the frequency of T cells. As ex-
pected, we observed a significant infiltration of CD3+ cells in
empty MP-treated mice (Figures 2A and 2B). Consistent with
clinical score data, Rapa MPs did not reduce CD3+ cell infiltra-
tion, resulting in frequencies that were similar to that of sections
from empty MP-treated mice. Both MOG MPs and MOG/Rapa
MPs drove a significant reduction in infiltration compared with
empty MP- and Rapa MP-treated mice (Figure 2B). Compared
with MOG MPs, a trend of reduced infiltration was observed
when co-loaded MPs were administered, though this result
was not statistically significant. Thus, i.LN. delivery of MPs drove
significant changes in the pathogenic T cell populations at a site
that is anatomically distinct from the injection site, inguinal LNs,
which are non-CNS-draining nodes.
Localization of Self-Antigen and Rapa in LNs Alters
Tissue Composition
The decrease in T cells in the CNS motivated study of how the
frequency and number of T cells changed in LNs, a key site of2942 Cell Reports 16, 2940–2952, September 13, 2016T cell expansion and polarization. To analyze the impact of these
signals on the cellular composition of injected LNs, mice were
treated on day 10, then flow cytometry was used to measure
the frequency and number of T cell and antigen-presenting cell
(APC) populations in the treated LN (Figure 2C). MOG MPs,
Rapa MPs, and MOG/Rapa MPs all drove a local decrease in
the frequency of CD4+ T cells compared with empty MP controls
(Figures 2D and S3); this decrease was greatest in mice treated
withMOG/RapaMPs.MOG/RapaMPswere also the only formu-
lation that caused a significant decrease in the frequency of
CD8+ T cells in treated LNs (Figures 2E and S3). Despite the
reduced frequencies in both T cell subsets, we observed a sta-
tistically similar number of cells in MOG/Rapa MP-treated LNs
relative to empty MPs and an increase in the number of CD4+
(Figure 2F) and CD8+ (Figure 2G) T cells followingMOGMP treat-
ment. This reduction in frequency, but similar or increased num-
ber of T cells, led us to hypothesize that another immune cell type
(i.e., APCs) was increasing in both frequency and number to ac-
count for some or all of the remaining cell population.
Relative to treatment of LNs with empty MPs, both MOG MPs
and MOG/Rapa MPs significantly increased the frequency of
cells expressing a classic DC marker (CD11c) (Figure 2H);
RapaMPs also increased the frequency of DCs, but not to a level
that was statistically significant (Figure 2H). Similar outcomes
were observed in analyzing the number of CD11c+ cells (Fig-
ure 2J), as well as the number and frequency of cells expressing
a classic macrophage marker (F4/80), but only MOG MPs
caused a significant increase in these populations (Figures 2I
and 2K). These results were generally consistent with the idea
that T cell frequencies, but not numbers, decreased in treated
nodes, while APC populations increased. Taken together, our
findings in Figures 1 and 2 confirm a critical role for self-antigen
in controlling EAE, including reorganization of cellular composi-
tion in injected LNs and infiltration of T cells into the CNS, as
well as a synergistic effect conferred by the inclusion of Rapa
in depots. These results also suggest that therapeutic efficacy
is antigen specific and impacts both innate and adaptive re-
sponses. Thus, we selected the most potent formulation,
MOG/Rapa MPs, to probe the local tissue- and cell-level
changes in LNs that lead to systemic tolerance.
Localization of Self-Antigen and Rapa in LNs Alters
Tissue Organization and Phenotype
To explore the local changes in the organization of treated LNs,
mice were injected on day 10, and then histological analysis
was carried out on day 15 (Figure 3A). These experiments re-
vealed a classic follicular organization of B cells and T cells with
interspersed DCs in LNs treated with empty MPs (Figure 3B). In
contrast, LNs injected with MOG/Rapa MPs exhibited increases
in DCs (Figure 3C, red signal), consistent with flow cytometry re-
sults (Figure 2H). This finding motivated more quantitative study
of LN structural organization following MP treatment. Thus, we
prepared sections from replicate animal groups, andweanalyzed
the expression of CD11c, stromal features of LNs, and a proto-
typical TREGmarker, forkhead box P3 (Foxp3) (Figure 3D), among
at least 20 sections as a function of area. Similar to preliminary tis-
sue staining (Figures 3B and 3C) and flow cytometry (Figure 2H)
results, calculation of the frequency of CD11c+ area revealed a
Figure 2. The i.LN. Injection of MPs Re-
strains Inflammatory Cell Infiltration into the
CNS and Alters Local Cell Compartments
Mice were induced with EAE, treated i.LN. with the
indicated MP formulations (n = 4) on day 10, and
then spinal cords were isolated on day 15.
(A) Immunofluorescent analysis of sections of the
spinal cord shows the expression of CD3 (green),
DAPI (blue), and an overlay. Scale bar, 100 mm. An
inset of the overlay channel is shown on the far right
column. Scale bar, 10 mm.
(B) Quantification of the frequency of CD3+ cells in
spinal cord sections shown in (A) following treat-
ment with empty MPs (n = 23), MOG MPs (n = 28),
Rapa MPs (n = 27), or MOG/Rapa MPs (n = 24).
Statistical analysis was performed using one-way
ANOVA with a Tukey post-test to compare the
means of all groups.
(C) In similar experiments, mice were induced with
EAE, treated i.LN. with the indicated MP formula-
tions (n = 4–6) on day 10, and then treated LNswere
isolated 2 days later.
(D–G) The frequencies of (D) CD4+ T cells (CD3+/
CD4+) and (E) CD8+ T cells (CD3+/CD8+) and the
numbers of (F) CD4+ and (G) CD8+ T cells were
quantified.
(H–K) The frequencies of (H) macrophages (F4/80+)
and (I) dendritic cells (DCs, CD11c+) and (J and K)
the numbers of these populations in treated LNs
were determined. Statistical analyses in (D)–(K)
were performed using one-way ANOVA with a Tu-
key post-test to compare each group to emptyMP-
treated controls. Data in (D)–(K) represent mean ±
SEM (*p% 0.05, **p% 0.01, ***p% 0.001, and ****p
% 0.0001).
See also Figure S3.statistically significant increase following MOG/Rapa MP treat-
ment relative to empty MPs (Figure 3E).
To assess whether these local changes in APCs were accom-
panied by altered expression or localization of TREGS, we
analyzed the number of Foxp3+ cells per area in the cortical ridge
of LNs (Figure 3D)—indicated by co-localization with a stromal
marker, ER-TR7—a structural microdomain associated with
TREG localization during tolerance (Warren et al., 2014). Enumer-
ation of Foxp3 staining revealed that, relative to treatment withCell Reportsempty MPs, MOG/Rapa MPs drove a
significant increase in the accumulation
of Foxp3+ cells in the cortical ridge
(Figure 3F).
Control of Autoimmunity Is
Dependent on i.LN. Delivery and
Encapsulation of Self-Antigen
Our flow cytometry and immunofluores-
cent analyses led us to hypothesize that
local delivery of MOG and Rapa drives
recruitment of DCs due to the presence
of MOG in animals with active EAE. In
addition, the altered cellular composition
of treated LNs and increase in the pres-
ence of TREGS localized in tolerogenic subdomains motivated
analysis of how cells in these tissues respond to an encounter
of self-antigen. Thus, we next characterized the inflammatory
recall responses in cells isolated from treated LNs at different
time points before and after MP treatment. On day 9 (i.e., prior
to MP treatment), restimulation of cells from LNs with MOG pep-
tide induced high levels of IL-17 (Figure 4A), GM-CSF (Figure 4B),
and IFN-g (Figure 4C) secretion. In contrast, no effect was
observed in response to an irrelevant peptide from ovalbumin16, 2940–2952, September 13, 2016 2943
Figure 3. MOG/Rapa MPs Elicit Changes in the Organization and Composition of Treated LNs
(A) Mice were treated i.LN. on day 10 post-EAE induction, and the injected inguinal LNs were excised on day 15.
(B and C) Immunofluorescent analysis of LNs injected with (B) empty MPs or (C) MOG/Rapa MPs shows B cells (B220+, cyan), T cells (CD3e+, green), and DCs
(CD11c+, red). Scale bars, 100 mm.
(D) Images of the cortical ridge of LNs, injected with empty MPs or MOG/RapaMPs, show DCs (CD11c+, red), reticular fibroblasts (stroma, ER-TR7+, green), high
endothelial venules (HEVs, PNAd+, blue), Foxp3+ cells (cyan), and an overlay. Scale bars, 100 mm. An inset of the overlay channel is shown on the far right column.
Scale bar, 10 mm.
(E and F) Quantitative image analysis was used determine the frequencies of (E) DCs and (F) Foxp3+ cells following empty MP (n = 23) or MOG/Rapa MP (n = 20)
treatment in the cortical ridge of sections like the representative images shown in (D). Statistical analyses in (E) and (F) were two-tailed Student’s t tests.(OVA, Figure S4), consistent with the myelin-specific inflamma-
tory response associated with disease. This local inflammatory
response in the inguinal LN is expected in induced MS models,
since inguinal LNs drain the peripheral sites used to induce dis-
ease. At time points after i.LN. injection, MOG/Rapa MPs gener-
ally reduced inflammatory cytokine secretion during restimula-2944 Cell Reports 16, 2940–2952, September 13, 2016tion relative to treatment with empty MPs (Figures 4A–4C).
However, these decreases were significant only on day 15 for
IL-17 and GM-CSF. Interestingly, when we analyzed similar cul-
tures prepared from splenocytes, significant reductions in IL-17
were observed at days 12 and 15 (Figure 4D), as well in GM-CSF
(Figure 4E) and IFN-g (Figure 4F) at day 12. Together, these
Figure 4. i.LN. Delivery and Antigen Encapsulation Restrain EAE and MOG-Triggered Inflammation
(A–F) Secretion of (A) IL-17, (B) GM-CSF, and (C) IFN-g in cells from treated LNs and (D–F) spleens stimulated ex vivo with MOG. Identical groups (n = 3–6) were
prepared for each time point and tissues were isolated before (day 9) or after (days 12, 15, and 18) i.LN. treatment on day 10. In (A)–(F), t tests were used to
compare empty MP and MOG/Rapa MP treatments at each time point.
(G) Benchmarking i.LN. injection against peripheral intramuscular (i.m.) injection is shown.
(H–J) The (H)mean clinical score, (I) meanmaximum score, and (J) incidence of disease inmice treated on day 10 (Tx, green arrow) post-EAE induction with empty
MPs i.LN. (n = 7), MOG/Rapa MPs i.LN. (n = 8), or an equivalent dose of i.m. MOG/Rapa MPs (n = 7). Statistical analysis in (H) was performed using two-way
ANOVA with a Tukey post-test, in (I) with a one-way ANOVA with a Tukey post-test, and in (J) with a log-rank test.
(K) Secretion of IFN-g after MOG or OVA restimulation of splenocytes on day 21. Statistical analysis in (K) was performed using one-way ANOVA with a Tukey
post-test to compare each group to a control group of cells isolated from mice treated with empty MPs i.LN. and pulsed with MOG.
(L and M) The (L) mean clinical score and (M) relative body weight of mice induced with EAE and treated i.LN. on day 10 with either empty MPs (n = 7) or soluble
MOG peptide mixed with Rapa MPs (n = 7). Statistical analyses in (L) and (M) were performed using multiple t tests, one at each time point, with a Holm-Sidak
post-test correction for multiple comparisons. Data in all panels represent mean ± SEM (*p% 0.05 and **p% 0.01).
See also Figure S4.results indicate that local introduction of MOG/Rapa MPs to LNs
can control disease while reducing self-antigen-triggered inflam-
mation in both treated and non-treated tissues.As LN delivery of MPs drove both local and systemic effects,
we sought to test the importance of localization of signals in
LNs for the development of tolerance. Mice were induced withCell Reports 16, 2940–2952, September 13, 2016 2945
EAE and treated on day 10 with MOG/Rapa MPs either i.LN. or
intramuscularly (i.m.) to mimic a common peripheral vaccination
route (Figure 4G). Compared with empty particles administered
i.LN. i.m. injection of MOG/Rapa MPs provided no significant
improvement to disease progression scores (Figure 4H), severity
(Figure 4I), or incidence (Figure 4J). In contrast, a matched dose
of MOG/Rapa MPs administered i.LN. again caused a potent
therapeutic impact (Figures 4H–4J). Further, to test how the
site of injection impacted systemic protection against inflamma-
tion, cells were collected from the spleens on day 21 and re-
stimulated with either MOG or OVA peptide. In cells isolated
from mice treated with empty MPs, restimulation with MOG
drove a significant increase in the secretion of IFN-g (Figure 4K)
compared with OVA stimulation. The i.LN. treatment with MOG/
Rapa MPs, but not with i.m. injection, resulted in a significant
reduction in IFN-g secretion following MOG pulse (Figure 4K).
Since attenuation of EAE and inflammatory responses re-
quired local i.LN. delivery, we next tested whether encapsulation
of signals was required for efficacy. Owing to the poor solubility
of Rapa and the miniscule volumes used for i.LN. injection, we
were unable to formulate admixed (i.e., without MPs) treatments
of soluble MOG and Rapa as controls. Thus, Rapa MPs were
mixed with soluble MOG and administered i.LN. 10 days after
EAE induction to assess the role of antigen co-encapsulation.
We observed no significant differences between empty MP con-
trols and soluble MOG + Rapa MPs with respect to either clinical
score (Figure 4L) or relative body weight (Figure 4M). These find-
ings indicate that both antigen encapsulation and local LN injec-
tion of MOG/Rapa depots play critical roles in tolerance.
Restraint of Autoimmunity Is Myelin Specific
Together, our results suggest a scenario where i.LN. treatment
results in antigen presentation with limited inflammation. We hy-
pothesized that this local LN reprogramming also might drive
TREG expansion and the development of tolerance in a myelin-
dependent manner. To investigate this hypothesis, we directly
studied the importance of including disease-relevant myelin an-
tigen in the restraint of EAE-induced paralysis and underlying
changes in immune cell function. Mice were treated on day 10
with empty MPs, MOG/Rapa MPs, or MPs encapsulating Rapa
and an irrelevant antigen, OVA (OVA/Rapa MPs). Cells from the
treated LNs and spleen were isolated, restimulated with MOG
peptide, and then the secretion of inflammatory cytokines was
analyzed. Surprisingly, both MOG/Rapa MPs and OVA/Rapa
MPs caused significant and equivalent local suppression of
IFN-g (Figure 5A), GM-CSF (Figure 5B), and IL-17 (Figure 5C)
compared with empty MP-treated controls. Similar effects
were observed in the spleen (Figures 5D–5F), but the differences
were more modest, with statistically significant effects only
observed for IL-17 (Figure 5F). We also observed a trend that
the lowest inflammatory cytokine levels were associated with
MOG/Rapa MPs.
Since the inclusion of disease-relevant antigen in depots
was not critical to reduce inflammatory recall response, we hy-
pothesized MOG/Rapa depots might more effectively expand
TREGS that can control pathogenic populations. This hypothesis
was supported by our observation above of significant reorgani-
zation of treated LNs with respect to Foxp3 localization in the2946 Cell Reports 16, 2940–2952, September 13, 2016cortical ridge following MOG/Rapa MP treatment (Figures 3D
and 3F). However, when we analyzed the frequency of CD4+/
CD25+Foxp3+ among all cells, rather than in structural microdo-
mains, we observed only a trend of increased TREG frequency af-
ter treatment with either MOG/Rapa or OVA/Rapa MPs, findings
that were not statistically significant (Figures 5G, 5H, top, and
S5). In stark contrast, however, MOG/Rapa MPs significantly
increased the frequency of TREGS in non-injected tissues, pooled
untreated LNs and spleen, compared with OVA/Rapa MPs and
empty MPs (Figures 5G, 5H, middle and bottom, and S5).
We next tested if these changes in immune cell function and
phenotype might have differential implications for disease pro-
gression. Mice were again induced with EAE, treated with
MPs as above, and monitored for disease symptoms. Strikingly,
mice treated with empty MPs or OVA/Rapa MPs developed
paralysis that was severe and equivalent (Figures 5I–5K), while
MOG/Rapa MPs dramatically improved clinical scores (Fig-
ure 5I), body weight (Figure 5J), and disease incidence,
(Figure 5K).
i.LN. Injection of MOG/Rapa MPs Drives the
Accumulation of TREGS in CNS-Draining LNs and
Reverses Autoimmunity
Together, the results in Figure 5 support a mechanism by which
non-specific suppression occurs at the site of injection due to
local Rapa introduction but whereby treatment with MPs also
incorporating myelin drives the expansion of TREGS that circulate
systemically to other tissues and sites of disease. This hypothe-
sis motivated the study of the frequency and localization of
Foxp3 expression in a key non-treated disease-relevant tissue,
cervical LNs, which drain the CNS. For these studies, mice
were induced with EAE and treated with empty MPs or MOG/
RapaMPs on day 10; 5 days later, the cervical LNs were excised
and analyzed by immunofluorescent analysis (Figure 6A). Quan-
titative analysis of at least 20 sections for each MP treatment re-
vealed a statistically similar frequency of DCs in both MP treat-
ments (Figure 6B) but a large increase in the number of Foxp3+
cells in the cortical ridge of LNs (Figure 6C). These data support
the hypothesis that MOG/Rapa depots delivered to non-CNS-
draining LNs increase TREG frequencies in distant LNs that drain
the sites of disease during MS.
Since local reprogramming of LNs resulted in strong systemic
effects that generated antigen-specific control of disease, we
last tested if this approach could reverse established disease.
In these studies, mice were treated with a single injection of
MOG/Rapa MPs or empty MPs at the peak of EAE (day 16).
MOG/Rapa MPs drove a dramatic reduction in mean clinical
score (Figure 7A), reversing paralysis and promoting weight
gain (Figure 7B). Strikingly, while 100% of mice treated with
empty MPs exhibited sustained severe disease, 75% of MOG/
Rapa MP-treated mice experienced durable reductions in clin-
ical score of at least two points (Figures 7C and 7D). Thus, a sin-
gle i.LN. treatment with MOG/Rapa MPs restored CNS function,
even when administered at the peak of disease. Together, these
findings suggest that i.LN. injection is not only a tool to study the
role of specific therapeutic components in tolerance but also a
powerful approach to generate antigen-specific control of dis-
ease, even when intervention occurs late in established disease.
Figure 5. Incorporation of Self-Antigen Is
Required for TREG Induction and Attenua-
tion of Disease, but Not for Local Suppres-
sion of Inflammation
(A–C) Mice were induced with EAE and treated
i.LN. on day 10 with empty MPs, OVA/Rapa MPs,
or MOG/Rapa MPs (n = 4 for each MP formula-
tion). On day 21, cells were isolated from treated
LNs and restimulated with MOG peptide, and
secretion of (A) IFN-g, (B) GM-CSF, and (C) IL-17
was measured.
(D–F) Similar analyses were performed on cells
isolated from splenocytes.
(G and H) The (G) scatterplots and (H) mean TREG
(CD25+Foxp3+ among CD4+) frequencies in
treated inguinal LNs (top), non-treated axillary and
brachial LNs (middle), and spleens (bottom) after
i.LN. injection on day 10 post-EAE induction and
analysis on day 12, are shown (n = 4–6 for eachMP
formulation).
(I–K) The (I) mean clinical score, (J) relative body
weight, and (K) disease incidence of mice induced
with EAE and treated i.LN. on day 10 (Tx, green
arrows) with empty MPs (n = 7), OVA/Rapa MPs
(n = 8), or MOG/Rapa MPs (n = 8). Statistical an-
alyses in (A)–(F) and (H) were performed using one-
way ANOVA with a Tukey post-test; all statistically
significant differences are indicated. Statistical
analyses in (I) and (J) were performed using two-
way ANOVAwith a Tukey post-test and in (K) using
a log-rank test. Data in all panels represent mean
± SEM (*p% 0.05, **p % 0.01, ***p% 0.001, and
****p% 0.0001).
See also Figure S5.DISCUSSION
The need for more effective and selective treatments for MS
has stimulated new clinical trials aimed at myelin-specific or
personalized therapies (Lutterotti and Martin, 2014). These ap-
proaches focus on cell-based adoptive transfer strategies, forCell Reportsexample, peripheral blood mononuclear
cells coupled to myelin peptides, or pa-
tient-specific, myelin-reactive, irradiated
T cells. In parallel, several preclinical re-
ports describe soluble treatments or
biomaterial-based approaches to deliver
self-antigen, regulatory small molecules,
or both to restrain self-reactivity (Clem-
ente-Casares et al., 2016; Esposito
et al., 2010; Gammon et al., 2015; Getts
et al., 2012, 2014; Ho et al., 2005; Hunter
et al., 2014; Maldonado et al., 2015; Tsai
et al., 2010; Yeste et al., 2012). While
these approaches demonstrate exciting
opportunities for translation toward the
goal of more effective and selective con-
trol of human disease, the approaches
reflect different strategies in the immuno-
modulatory signals delivered. As noted,
some studies demonstrate co-delivery
of self-antigen and a regulatory signal confers therapeutic ef-
fects (Maldonado et al., 2015; Yeste et al., 2012), while other re-
ports suggest that changing the physical form of self-antigen can
trigger existing debris clearance pathways to promote tolerance
in the absence of explicit immunoregulatory cues (Getts et al.,
2012, 2014; Hunter et al., 2014). Further, studies in animal16, 2940–2952, September 13, 2016 2947
Figure 6. MOG/Rapa MPs Promote Tolerogenic Reorganization and Accumulation of TREGS in CNS-Draining LNs
Mice were induced with EAE and treated i.LN. on day 10 with empty MPs or MOG/Rapa MPs (n = 4), and cervical LNs were excised for analysis 5 days later.
(A) Immunofluorescent analysis of cervical LNs shows DCs (CD11c+, red), reticular fibroblasts (stroma, ER-TR7+, green), HEVs (PNAd+, blue), Foxp3+ cells (cyan),
and an overlay. Scale bars, 100 mm. An inset of the overlay channel is shown on the far right column. Scale bar, 10 mm.
(B and C) Quantitative image analysis was used determine the frequency of (B) DCs and (C) Foxp3 following empty MP (n = 21) or MOG/Rapa MP (n = 22)
treatment in the cortical ridge of sections like the representative images shown in (A). Statistical analyses were two-tailed Student’s t tests.models and human MS identify the presence of myelin self-anti-
gen in LNs (Korn et al., 2007; Mohammad et al., 2014; van Zwam
et al., 2009b). These results indicate that CNS antigens are
present in peripheral sites of T cell polarization during disease,
suggesting that delivery of tolerogenic signals alone may be
sufficient to restrain myelin-specific self-attack. Thus, the role
of candidate immunomodulatory signals and combinations of
these signals is not well defined, particularly in the context of
the impact on the LN microenvironment.
The connections between systemic tolerance and local LN
function are of particular interest to MS, since pathogenic
T cells are armed in LNs prior to CNS infiltration. Past studies,
for example, revealed that excision of CNS-draining LNs restricts
T cell infiltration to the CNS and limits EAE in rat models (van
Zwam et al., 2009a). In addition, recent work has identified
APCs and T cells in newly discovered lymphatics that connect
the CNS with cervical LNs outside the CNS (Aspelund et al.,
2015; Louveau et al., 2015). These findings, along with human tri-
als using i.LN. injection of free antigens for cancer or allergy ther-
apy (Senti and K€undig, 2015), suggest clinical opportunities
based on controlling the local response to myelin in LNs during
MS as a direct route to promote myelin-specific tolerance.
Thus, one outcome of our work is a newpossibility for locally pro-2948 Cell Reports 16, 2940–2952, September 13, 2016gramming LN function, through co-delivery from depots, local
controlled release, or other biomaterial-enabled features, to
generate systemic and specific control of disease. In addition
to assessing clinical potential, we sought to use i.LN. depots
as a tool to study how the local inflammatory or tolerogenic state
of LNs controls the magnitude and specificity of systemic toler-
ance. This platform provides a unique opportunity to probe the
spatial and temporal dynamics of immune response to self-anti-
gens; in contrast, approaches that employ systemic injections or
repeated doses complicate these kinds of perturbations.
Our experiments reveal that reprogramming discrete LNs can
generate systemic tolerance. The dependence of therapeutic
efficacy on i.LN. delivery of encapsulated, disease-relevant
self-antigen highlights three unique results of this platform. First,
a role for controlled kinetic release frommicron-scale depots re-
tained in LNs following injection (Andorko et al., 2014; Jewell
et al., 2011) is supported by the observation that substitution
of soluble myelin self-antigen eliminates therapeutic efficacy
(Figure 4). Second, perhaps in parallel, direct deposition of
MPs in LNsmay drive higher frequency encounters with resident
APC populations that have been shown to promote tolerance
(Maldonado et al., 2015). This approach might provide a means
to bypass the relatively inefficient drainage and trafficking
Figure 7. A Single i.LN. Dose of MOG/Rapa MPs Reverses Disease-
Induced Paralysis
(A and B) Mice were treated at the peak of EAE (day 16; Tx, green arrow) using
a single i.LN. dose of empty MPs (n = 11) or MOG/Rapa MPs (n = 12), and (A)
mean clinical score and (B) weight were monitored.
(C) Persistence of disease is shown, with recovery from disease defined as at
least a two-point reduction in clinical score relative to the score just prior to
treatment.
(D) Score distribution of mice in (A)–(C) just before treatment (day 16, left) and
at day 49 (right).
Statistical analysis in (A) and (B) was performed using multiple t tests, one at
each time point, with a Holm-Sidak post-test correction for multiple compar-
isons, and in (C) using a log-rank test. Data in all panels represent mean ± SEM
(*p% 0.05, **p% 0.01, ***p% 0.001, and ****p% 0.0001).mechanisms by which signals traditionally reach LNs and spleen
following peripheral injection (Andorko et al., 2014, 2015; Jewell
et al., 2011) and, therefore, enhance efficacy compared with i.m.
delivery of a matched dose tested here (Figure 4). Third, the
observation that both MOG MPs and MOG/Rapa co-loaded
MPs attenuate disease (Figure 1) suggests a possible contribu-
tion from altered trafficking or more efficient processing of anti-
gen in particulate form relative to soluble antigen (Getts et al.,
2012, 2014; Hunter et al., 2014).
In addition to the need for encapsulation and targeted LN
injection, ex vivo restimulation further revealed a less inflamma-
tory milieu was established in LNs by MOG/Rapa depots
(Figures 4A–4C and 5A–5C). We observed a decrease in the
myelin-triggered secretion of three key cytokine drivers of inflam-
mation during disease in mice and humans (IL-17, IFN-g, and
GM-CSF). In particular, IL-17 is a characteristic cytokine
secreted by TH17 cells, while IFN-g is a broad pro-inflammatory
signal secreted by TH1 subsets during autoimmunity (Dendrou
et al., 2015). Further, GM-CSF has been shown to be secreted
by self-reactive T helper cells, triggering an inflammatorycascade that enhances pathogenic monocyte-derived cell infil-
tration into the CNS and subsequent tissue damage (Croxford
et al., 2015). Together, these findings support a possible mecha-
nism by which myelin is presented in LNs but whereby the
response is altered by the presence of TREG-inducing signals in
the case of MOG/Rapa MPs, or at least a lack of co-stimulation
in the case of MOG MPs. Supporting this idea, we discovered
that MOG/Rapa MPs drive distinct remodeling of the LN stroma,
with Foxp3+ cells accumulating in the cortical ridge of LNs in
close proximity to high endothelial venules (HEVs)—routes of
T cell entry into LNs (Warren et al., 2014). Our measurements of
this phenomenon in treated LNs (Figures 4D and 4F) and non-
treated, CNS-draining LNs (Figures 6A and 6C) suggest that local
perturbation of LNswith self-antigen and Rapa promotes this tol-
erogenic reorganization.
After i.LN. injection of MOG/Rapa MPs, we also observed a
significant increase in the frequency of TREGS in the spleen and
pooled non-treated LNs relative to empty MPs or OVA/Rapa
MPs (Figures 5G and 5H). This result further underscores the
self-antigen-specific nature of efficacy, though new tools such
as MHC-II tetramer could help directly verify the antigen speci-
ficity of T cell receptors (TCRs) on the expanding TREGS (Nelson
et al., 2015). Interestingly, effects were least pronounced and
statistically insignificant in treated LNs (Figures 5G and 5H,
top). One explanation for this outcomemay be that local delivery
of myelin triggers resident myelin-reactive cells but little expan-
sion of regulatory cells occurs because Rapa inhibits prolifera-
tion. This hypothesis is supported by the discovery that, while
MPs encapsulating Rapa and the irrelevant antigen OVA did
not impact disease (Figures 5I and 5K), these particles caused
local suppression of inflammatory recall response equivalent to
that of MOG/Rapa MPs (Figures 5A–5C) in treated nodes. There
was an intermediate reduction in the spleen, an untreated site,
likely due to non-specific, systemic effects of Rapa. Supporting
this hypothesis, recent literature demonstrates that systemic
treatments with modulatory or suppressive drugs can cause dif-
ferential impacts on inflammatory responses in different tissues,
findings that also illustrate the utility of having a tool to directly
probe how signals in one tissue impact the course, efficiency,
and durability of tolerance (White et al., 2014). One further ratio-
nale for co-delivery of tolerogenic signals (e.g., Rapa) with self-
antigen is to mitigate the risk of exacerbating disease with a
therapy containing disease-relevant antigen during active auto-
immunity (Maldonado et al., 2015).
Our findings reveal antigen-specific tolerance can begenerated
with striking efficacy by locally reprogramming LNs, results
demonstrating the unique potential of this strategy to study and
combat autoimmunity. Some of the important follow-up studies
include the need to further assess the trafficking of T cells from
treated LNs to the cervical LNs and CNS, and importantly, to
confirm remyelination, a critical criterion for human MS therapy.
The functional selectivity of tolerance also should be assessed
by confirming intact pro-immune responses to exogenous anti-
gensafter recovery. Lastly,mousemodelsdonot fully recapitulate
the myelin reactivity and epitope spreading present in human dis-
ease. The modular nature of the engineering approach reported
here allows facile incorporation of multiple peptide epitopes and
could support future studies in other models or in humans toCell Reports 16, 2940–2952, September 13, 2016 2949
assess these dynamics. Thus, this work demonstrates unique po-
tential to study, control, and reverse established autoimmune dis-
ease in a selective fashion by modulating local LN function.EXPERIMENTAL PROCEDURES
Materials and Reagents
Myelin oligodendrocyte glycoprotein (MOG35–55) and ovalbumin (OVA323–339)
peptides, with or without a fluorescein isothiocyanate (FITC) tag conju-
gated to the N terminus, were synthesized by GenScript at R98% purity.
Poly(lactide-co-galactide) (PLGA) and poly(vinyl alcohol) (PVA) were pur-
chased from Sigma. Rapa was purchased from LC Laboratories. Antibodies
for flow cytometry, including CD16/CD32, V450 CD4 (clone RM4-5), PE-Cy7
CD25 (clone PC61), Alexa Fluor 488 Foxp3 (clone MF23), PE-Cy7 CD3 (clone
145-2C11), FITC CD4 (clone RM4-5), PE CD8 (clone 53-6.7), PE F4/80 (clone
T45-2342), and allophycocyanin-Cy7 CD11c (clone HL3), were purchased
from BD Biosciences.
Particle Synthesis
Double-emulsion/solvent evaporation was used to generate degradable PLGA
MPs as previously reported (Andorko et al., 2014; Jewell et al., 2011). Briefly,
an inner aqueous phase was prepared as either 500 ml water or 1 mg peptide
(i.e., MOG or OVA) dissolved in 500 ml water. The inner aqueous phase was
sonicated with an organic phase comprised of 80 mg PLGA dissolved in
5 ml dichloromethane for 30 s at 12 W to form a water/oil emulsion. In MP for-
mulations containing Rapa, polymer solution was added to a vial containing
2 mg dried drug before sonication to incorporate Rapa into the organic phase.
For all formulations, the primary emulsion was homogenized with 40 ml 2%
PVA for 3 min at 16,000 rpm to form final, stabilized double emulsions. Parti-
cles were stirred for 16 hr to allow for solvent evaporation. After 16 hr, MPs
were poured through a 40-mm cell strainer to remove any aggregates and
collected by centrifugation (5 min, 5,000 3 g, and 4C). The supernatants
were decanted and MPs were washed three times with 1 ml water, collected
by centrifugation between each wash, and resuspended in water.
Particle Characterization
Particle size wasmeasured using an LA-950 laser diffraction size analyzer (Ho-
riba). A known aliquot of MPs was dried under air, and the dry mass was used
to calculate the total particle yield and normalized to the polymer input (i.e.,
percentage yield). The loading of peptide was quantified viaMicro BCAProtein
Assay Kit (Thermo Scientific Pierce) as previously described (Sah, 1997). The
loading of Rapa wasmeasured via UV/Vis spectrophotometry after dissolution
of a knownmass of dried particles in DMSO. For all cargos, standard curves of
known concentrations were used to calculate loading, reported as the mass of
cargo per mass of particles and normalized to the input to synthesis (i.e.,
encapsulation efficiency). For studies involving immunofluorescent analysis
of intra-nodal MP deposition, fluorescently tagged MOG peptide (FITC-
MOG) was incorporated into the inner aqueous phase, and 10 ml fluorescent
dye (Vybrant DiI Cell-Labeling Solution, Molecular Probes) was added to the
organic phase of MP synthesis to enable visualization of particles and encap-
sulated cargo in tissue sections.
EAE Induction and Monitoring
EAE was induced in 10- to 11-week-old female C57BL/6J mice (The Jackson
Laboratory) according to the manufacturer’s instructions (Hooke Laboratories).
Briefly, on day 0, mice were administered two subcutaneous injections of
an emulsion of complete Freund’s adjuvant and a peptide fragment of MOG
(MOG35–55). Then 2 and 24 hr later, mice were administered pertussis toxin via
intraperitoneal injections. Beginning 7 days after induction, mice were moni-
tored daily for weight fluctuation and symptoms of paralysis, which were as-
signed a clinical score to reflect disease severity (0, no symptoms; 1, limp tail;
2, hind limb weakness; 3, hind limb paralysis; 4, full hind limb and partial front
limb paralysis; and 5, moribund). Incidence of disease was defined as the first
day amouse exhibited a clinical score >0, and itwas reportedas thepercentage
of mice in each group with detectable symptoms of disease over time. Mean2950 Cell Reports 16, 2940–2952, September 13, 2016maximumscore of eachgroupwascalculatedbyaveraging themaximumscore
reached throughout the duration of the experiment of each mouse.
Immunizations
Doses of MP formulations were administered via non-surgical, direct i.LN. in-
jection as we previously described (Andorko et al., 2014; Jewell et al., 2011).
Briefly, 1 day prior to injection, mice were administered a bilateral injection
of tracer dye (Evans blue, Alfa Aesar) subcutaneously at the tail base and their
fur was removed with a mild depilatory cream. On the day of treatment, each
mouse received a single dose of indicated MP formulations, dissolved in the
appropriate final injection volume (2 3 10 ml). Immunizations were adminis-
tered as bilateral injections to the inguinal LNs, with each LN receiving half
of the total dose. Irrespective of formulation, each mouse was treated with
2 mg MPs (i.e., 1 mg per LN), containing the indicated cargos at the levels
shown in Table S1. In control studies, matched masses of MPs were adminis-
tered via bilateral i.m. injections in the caudal thigh, with injection volumes
adjusted to 2 3 25 ml.
Tissue Processing
At the indicated time points, injected inguinal LNs, spleen, and, in some cases,
non-treated axillary and brachial LNs were excised and processed by manual
dissociation through a 40-mm cell strainer. Cells were collected by centrifuga-
tion (5min, 8003 g, and 4C). Spleen samples were resuspended in Ack lysing
buffer (Invitrogen) to remove red blood cells and then washed with PBS. LN
cells were washed with PBS without lysis. Cells were counted using an auto-
mated cell counter (NanoEnTek) or counting beads according to the manufac-
turer’s instructions (BD Biosciences), and they were either plated for ex vivo
restimulation assays or analyzed immediately by flow cytometry.
Ex Vivo Restimulation Assays
To characterize cellular response after an encounter of disease-relevant (i.e.,
MOG) or irrelevant (i.e., OVA) antigen, a uniform number of cells (1 3 106)
was plated from each tissue sample in duplicate. One well was restimulated
in culture with MOG (25 mg/ml) and the second well received a matched
dose of OVA peptide. After 48 hr of incubation, culture supernatants were
collected for analysis by ELISA.
ELISA
All ELISAs were performed according to the manufacturer’s instructions for
IL-17 (R&D Systems), GM-CSF (R&D Systems), and IFN-g (BD Biosciences)
detection. Supernatants were collected from cell culture samples and
analyzed at 1–203 dilutions.
Flow Cytometry Experiments
Immediately after tissue excision and processing, cells were washed with
200 ml 1% BSA in 13PBS, resuspended in Fc block (anti-CD16/CD32), and
incubated for 10 min at room temperature to inhibit non-specific binding. Cells
were then incubated with the indicated antibodies against cell surface
markers, including CD3, CD4, CD8, F4/80, CD11c, and CD25. Cells were
washed to remove unbound antibody, and then either stained for viability
(DAPI, Invitrogen) and analyzed immediately or fixed and permeabilized to
enable staining for intracellular markers (i.e., transcription factors). After fixa-
tion and permeabilization (Foxp3/Transcription Factor Staining Buffer Set,
eBioscience), cells were stained for expression of Foxp3, washed, and
analyzed. All analysis was performed on a FACS Canto II (BD Biosciences)
and data analysis was conducted using FlowJo version 10 (Tree Star).
Immunofluorescent Analysis
At the indicated time points, treated inguinal LNs, non-treated cervical LNs, or
spinal cords were excised and immediately submerged in OCT compound
(Tissue-Tek) and frozen. Cryosections were cut at 6 mm using a Microm HM
550 cryostat (Thermo Fisher Scientific). Sections were fixed with cold acetone
for 5 min, washed with PBS, and blocked with 5% donkey serum (Sigma)
and 5% goat serum (Sigma) in PBS for 30 min. Following a PBS wash,
samples were stained for 1 hr with primary antibodies against the indicated
markers, including T cells (CD3e, Rb pAb, Abcam), B cells (B220, clone
RA3-6B2, eBioscience), DCs (CD11c, Ham pAb, BD Pharmingen), HEVs
(PNAd, clone MECA-79, BD Pharmingen), stroma (ER-TR7, clone sc-73355,
Santa Cruz Biotechnology), and Foxp3 (Rb pAb, Abcam). Sections were
washed once with PBS and fluorescently conjugated secondary Ab was
applied for 45 min. Slides were washed three times in PBS for 5 min, fixed
with 4% paraformaldehyde (Electron Microscopy Sciences), treated with 1%
glycerol in PBS before mounting with Prolong Diamond Antifade Mountant
(LifeSciences), in some cases containing DAPI, and imaged using a confocal
microscope.
For quantitative analyses, tissues were collected 5 days after i.LN. injection
(i.e., day 15) of either empty MPs or MOG/RapaMPs (n = 4mice; eight injected
inguinal LNs, at least 16 cervical LNs, and four spinal cords). Quantitative anal-
ysis was performed on images of treated inguinal LNs, cervical LNs, and spinal
cords using Volocity image analysis software (PerkinElmer). For LN analyses,
the percentage of CD11c+ area was defined as the fraction of tissue area stain-
ing positive for CD11c among cortical ridge area, defined as the area positive
for ER-TR7. The threshold for positive area for both signals was defined using
appropriate iso-type control-stained sections. The number of Foxp3+ cells
among the cortical ridge was similarly quantified using an iso-type control to
define positive cells. In spinal cord analyses, the percentage of CD3+ area
was defined as the fraction of area staining positive for CD3 among the total
spinal cord area imaged. Similarly, an iso-type control was used to set the
threshold for positive area. All quantitative analysis was performed on at least
20 images of LN or spinal cord per MP formulation, and statistical analyses
were performed using two-tailed Student’s t tests.
In Vivo Study Design
On the day of induction, mice were screened to identify animals with the most
consistent starting body weights to be included in the study. Mice were then
induced with EAE, as described above, and randomized into treatment
groups. In studies involving late-stage therapy, the clinical scores of mice
were assessed and mice were randomized into two groups with equivalent
mean scores just before treatment. Mice were removed from studies accord-
ing to humane endpoints, including loss ofR25%of initial (day 0) body weight,
presentation with a clinical score of 4 for 2 consecutive days, or presentation
with a clinical score of 4.5 or 5 on a single day. In mechanistic studies designed
to investigate the kinetics of disease or tolerance, mice were induced with
EAE, randomized into groups, and identically treated groups of mice were
euthanized at the indicated time points for analysis. Data collection and ana-
lyses were not blinded and no outliers were excluded.
Statistics
Student’s t tests were used in comparisons of two groups and ANOVA was
used to compare three or more groups, with post-test corrections for multi-
ple comparisons as indicated in figure captions. Log-rank tests were used in
analyses of disease incidence or persistence. All tests were two-sided ana-
lyses and were performed using GraphPad Prism software. Error bars in all
panels represent mean ± SEM and p values % 0.05 were considered
significant.
Study Approval
All animal studies were carried out under the supervision of the University of
Maryland Institutional Animal Care and Use Committee (IACUC) in compliance
with local, state, and federal guidelines.
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